GlassScriptPhysician profile
Lorretta K Mccarthy
NPI 1033126248
$2,645.73
in general payments reported to CMS, 2019-2025
33 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $290 · 2021: $226 · 2022: $541 · 2023: $466 · 2024: $478 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $864.59 | 2021-2025 | |
| Pfizer INC. | $182.83 | 2020-2025 | |
| Novo Nordisk INC | $171.06 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.04 | 2019-2025 | Jardiance |
| Abbott Laboratories | $102.11 | 2019-2025 | Proclaim |
| Allergan, INC. | $101.67 | 2019-2020 | |
| Boston Scientific Corporation | $97.21 | 2021-2025 | General - Pain Management |
| Glaxosmithkline, LLC. | $82.23 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $80.44 | 2019-2025 | Airsupra |
| Sanofi-Aventis U.S. LLC | $78.46 | 2019-2025 | |
| Sanofi Pasteur INC. | $72.02 | 2020-2025 | |
| Heartflow, INC. | $67.97 | 2024 | |
| Novartis Pharmaceuticals Corporation | $59.75 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $46.88 | 2020-2024 | Gardasil 9, Gardasil, Capvaxive |
| Sumitomo Pharma America, INC. | $45.14 | 2024 | Gemtesa |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $41.24 | 2023-2025 | Injectafer |
| Dexcom, INC. | $37.25 | 2024-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $36.88 | 2023 | Myrbetriq, Veozah |
| Kestra Medical Technology Services, INC. | $35.94 | 2024-2025 | Assure Wcd |
| Inspire Medical Systems, INC. | $29.82 | 2024 | Inspire |
| Janssen Pharmaceuticals, INC | $29.80 | 2020-2022 | |
| Lilly USA, LLC | $29.67 | 2023-2025 | Mounjaro, Zepbound |
| Sunovion Pharmaceuticals INC. | $26.00 | 2022 | |
| Caldera Medical, INC | $25.26 | 2022 | |
| Amgen INC. | $22.27 | 2022 | |
| Atricure, INC. | $21.48 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.50 | 2025 | |
| Teleflex LLC | $17.40 | 2022 | |
| Halozyme INC | $17.17 | 2023 | |
| Nevro Corp. | $16.18 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.40 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.50 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorretta Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.